ArticleFrontiers in cardiovascular medicine2026

Ultra-early in-cath lab evolocumab achieves rapid lipid target attainment and lipid quality improvement in acute coronary syndrome: a real-world propensity score-matched study.

Yufeng Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.